Author:
Callier Shawneequa L.,Payne Perry W.,Akinniyi Deborah,McPartland Kaitlyn,Richardson Terry L.,Rothstein Mark A.,Royal Charmaine D. M.
Funder
National Human Genome Research Institute
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Sociology and Political Science,Anthropology,Health (social science)
Reference58 articles.
1. National Human Genome Research Institute. Whole genome association studies. 2011. https://www.genome.gov/17516714/2006-release-about-whole-genome-association-studies. Accessed 28 Feb 2021.
2. The US Food and Drug Administration; Center for Drug Evaluation and Research. Highlights of prescribing information: BIDIL® (isosorbide dinitrate and hydralazine hydrochloride) tablet, for oral use 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020727s005lbl.pdf. Accessed 30 Dec 2021.
3. Stein R. FDA approves controversial heart medication for blacks. The Washington Post 2005 June 24, 2005.
4. Callier SL, Cunningham BA, Powell J, McDonald MA, Royal CDM. Cardiologists’ perspectives on race-based drug labels and prescribing within the context of treating heart failure. Health Equity. 2019;3(1):246–53. https://doi.org/10.1089/heq.2018.0074.
5. Kahn, Jonathan 2013 Race in a Bottle: The Story of BiDil and Racialized Medicine in the Genomic Age, New York: Columbia University Press.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献